Peripheral Intravenous (IV) Catheter Market Size and Growth Report, 2033

Peripheral Intravenous (IV) Catheter Market Overview

The Peripheral Intravenous (IV) Catheter Market size was valued at USD 4120.56 million in 2024 and is expected to reach USD 6330.5 million by 2033, growing at a CAGR of 4.9% from 2025 to 2033.

The peripheral intravenous (IV) catheter market is an essential component of modern healthcare infrastructure, with over 2.3 billion units utilized globally in 2024. These devices are routinely used for fluid delivery, medication administration, and blood transfusions in hospitals, clinics, and ambulatory surgical centers. Short peripheral IV catheters accounted for more than 1.9 billion units, while integrated or closed IV catheters made up 400 million units. Hospitals remained the primary end users, accounting for more than 70% of catheter placements. In 2024, over 850 million peripheral IV catheterizations were performed in North America alone, with the U.S. leading due to widespread inpatient and emergency room usage.

Europe followed with more than 610 million catheterizations, while Asia-Pacific accounted for 580 million. The growing incidence of chronic diseases, coupled with increased surgical procedures—over 320 million performed globally in 2024—has boosted catheter demand. Technological advancements have led to the development of anti-bacterial coated catheters, which were used in over 112 million procedures. With 6,800 hospitals globally upgrading to integrated IV catheter systems, the market continues to experience strong growth in both developed and emerging healthcare systems.

Key Findings

Top Driver reason: Increased hospitalization rates and surgical procedures globally are driving demand.

Top Country/Region: The United States led the market with more than 620 million peripheral IV catheter procedures in 2024.

Top Segment: Short PIVCs dominated the market with over 1.9 billion units used worldwide in 2024.

Peripheral Intravenous (IV) Catheter Market Trends

The peripheral intravenous catheter market has experienced considerable transformation, shaped by advances in safety features, material technologies, and hospital protocols. In 2024, over 480 million IV catheters were equipped with safety-engineered features such as passive needle retraction systems and automatic locking mechanisms. These features reduced needlestick injury incidence by 28% in large hospitals across the U.S., U.K., and Canada.

The shift toward integrated or closed catheter systems continued, with more than 6,800 healthcare facilities transitioning to closed systems to reduce bloodstream infection rates. These systems were associated with a 23% reduction in catheter-related bloodstream infections (CRBSIs), a key driver in their adoption. Integrated PIVCs accounted for 400 million units in 2024, growing steadily in critical care settings.

The trend toward outpatient and home-based care also contributed to market changes. Over 112 million PIVCs were used in ambulatory surgical centers and home health settings in 2024, where ease of use and safety were primary selection criteria. Demand for PIVCs with anti-thrombogenic coatings rose, with more than 89 million units featuring this property, helping to reduce catheter occlusion rates by 14%.

Material innovations were another focus area. In 2024, over 320 million catheters were made from polyurethane, offering improved biocompatibility and flexibility. Silicone catheters, used in over 84 million cases, were preferred for patients requiring longer dwell times. Additionally, the demand for pediatric-specific IV catheters surged, with over 98 million child-size catheters sold in 2024, emphasizing improved insertion success rates and reduced vein trauma.

Asia-Pacific saw a rapid increase in catheter adoption due to expanded healthcare access. India alone used over 210 million catheters in 2024, driven by government-funded health initiatives and increased public hospital capacities. In Europe, hospitals in Germany, France, and Italy increasingly adopted catheters with ultrasound visibility for use in difficult venous access scenarios, totaling more than 63 million procedures.

Peripheral Intravenous (IV) Catheter Market Dynamics

Drivers

Rising demand for hospitalizations and intravenous treatments

Global hospitalization rates continue to rise due to chronic illnesses, infectious disease management, and surgical interventions. In 2024, more than 1.2 billion inpatient admissions were recorded globally, with 94% requiring at least one peripheral IV catheter insertion. This represents over 1.13 billion catheterizations tied directly to inpatient hospitalizations. Emergency room visits also spiked, with over 860 million visits globally, and IV catheter insertion rates exceeded 72% in acute care settings. High-volume hospitals in the U.S., China, and India recorded daily usage rates of over 2,400 catheters per facility. The increasing volume of procedures such as chemotherapy, hydration therapy, and pain management each requiring IV access—has fueled consistent product demand.

Restraints

Risk of complications and insertion failures

Despite their widespread use, peripheral IV catheters are associated with clinical risks such as infiltration, phlebitis, occlusion, and accidental dislodgement. In 2024, over 160 million complications were reported globally due to catheter-related incidents, with occlusion accounting for 39% and infiltration for 28% of these events. The average first-attempt insertion failure rate remained high at 28%, especially among obese and pediatric patients. In critical care units, up to 13% of catheters required premature removal due to complications, reducing cost-efficiency and patient satisfaction. Catheter-related bloodstream infections (CRBSIs) still occurred in 1.4% of cases worldwide, prompting demand for improved device design and infection control protocols. These challenges have limited the adoption of cheaper catheter products lacking advanced safety features.

Opportunities

Expansion of point-of-care and outpatient treatment settings

The shift toward decentralized healthcare and minimally invasive outpatient procedures is creating substantial new market opportunities. In 2024, more than 270 million outpatient surgeries and IV-based therapies were conducted in ambulatory surgical centers (ASCs) and home care environments. PIVC kits tailored for home health use—including pre-packaged flush syringes and securement dressings—saw a 38% rise in distribution volume. Hospitals and clinics in the U.S., Japan, and Australia introduced mobile catheter units with ultrasound guidance, enabling IV insertion in non-hospital environments. In India, government-backed rural health clinics used more than 24 million catheters in outreach immunization and fluid therapy programs. These applications offer growth potential for manufacturers offering easy-to-use, low-risk IV catheter products.

Challenges

High product pricing and regulatory barriers

Pricing pressures continue to challenge market expansion, especially in cost-sensitive healthcare systems. In 2024, the average cost per safety-engineered PIVC rose by 11.6% due to inflation in medical-grade polymer raw materials. Procurement budgets in public hospitals across Latin America and Southeast Asia remained stagnant, leading to a shift toward low-cost, basic IV catheters. However, lower-priced options often lacked safety mechanisms, contributing to a 24% higher incidence of needlestick injuries in developing nations. Regulatory clearance timelines also pose challenges. In Europe, new IV catheter models required compliance with updated MDR (Medical Device Regulation) standards, extending time-to-market by 8–10 months. These compliance hurdles slowed the launch of more than 42 new PIVC products in 2024.

Peripheral Intravenous (IV) Catheter Market Segmentation

By Type

Short PIVCs: Short peripheral intravenous catheters represented 83% of total usage, with over 1.9 billion units in 2024. These devices were most commonly used for short-term fluid and medication administration. Their dwell time averaged 72 hours. Stainless steel needles and polyurethane tubing were used in 92% of short PIVCs. Pediatric and geriatric variants accounted for 168 million units.
Integrated or Closed PIVCs: Integrated or closed systems accounted for 400 million units in 2024. These catheters offered enhanced safety with built-in extension tubing, needleless access ports, and passive safety locks. Their use was prevalent in intensive care units, oncology wards, and pediatric surgery departments. Over 72 million units featured antimicrobial coatings to reduce CRBSI risks.

By Application

Hospitals: Hospitals were the largest end-user group, using over 1.6 billion PIVCs in 2024. More than 680 million were used in surgical wards and ICUs. In trauma and emergency settings, IV access was initiated in over 480 million patients. Hospital protocols increasingly mandated first-attempt success rates above 85%, encouraging adoption of ultrasound-guided insertion.
Clinics: Clinics used more than 420 million IV catheters, mainly in infusion therapy and chronic disease management. Outpatient settings in Europe and North America performed 94 million catheterizations, particularly for hydration and vitamin therapy. Clinics preferred short PIVCs with simplified insertion kits to reduce nursing time.
ASCs (Ambulatory Surgical Centers): ASCs consumed around 260 million units in 2024. These centers required rapid deployment and cost-effective catheters for same-day procedures. Over 70% of devices used in ASCs were pre-packaged kits with included saline flushes and transparent dressings. Integrated PIVCs were used in 18% of high-risk outpatient surgeries.

Peripheral Intravenous (IV) Catheter Market Regional Outlook

North America

dominated the peripheral IV catheter market in 2024, with over 860 million units used across the United States and Canada. The U.S. alone accounted for more than 620 million units due to high hospitalization rates, widespread use of safety-engineered catheters, and strong insurance-backed medical infrastructure. Over 73% of U.S. hospitals standardized on integrated or safety-featured PIVCs, resulting in 220 million units sold with passive retraction or antimicrobial properties. Canada contributed 240 million units, with regional health authorities promoting single-use and eco-friendly materials.

Europe

followed with over 610 million units used in 2024. Germany, France, Italy, and the U.K. accounted for more than 76% of total European volume. Over 180 million catheters in Europe were used in emergency medicine and critical care departments. The EU’s push for infection control led to the adoption of antimicrobial-coated PIVCs, reaching 96 million units. Hospitals in Germany used over 58 million ultrasound-guided insertion systems, improving accuracy and reducing insertion failure by 21%.

Asia-Pacific

recorded more than 580 million units in 2024, with China and India leading the region. China utilized 310 million PIVCs, supported by hospital expansion and government-driven healthcare reforms. India used 210 million units, with increasing adoption in rural clinics and government hospitals. Japan contributed 38 million units, focusing on integrated PIVCs in geriatric care. More than 78 million PIVCs in Asia-Pacific were used in public immunization and maternal health campaigns.

Middle East & Africa

The region used over 210 million PIVCs in 2024. The UAE, Saudi Arabia, and South Africa accounted for over 140 million units. Government investments in emergency medicine and hospital infrastructure supported over 74 million procedures requiring IV catheterization. In Africa, more than 48 million units were distributed through NGOs and health programs for malaria, HIV, and TB treatment. Mobile medical units across 11 African countries used over 11 million PIVCs in outreach care.

List of Top Peripheral Intravenous (IV) Catheter Companies

B. Braun Melsungen
C.R. Bard
Smiths Medical
TERUMO CORPORATION
AngioDynamics
APEXMED International
Delta Med
EXELINT International
GaltNeedleTech
Global Medikit
Hospira
NIPRO Medical
RenovoRx

Top Two Companies with the Highest Share

Braun Melsungen:Supplied over 440 million units globally in 2024, maintaining leadership in both short PIVCs and integrated closed systems, with manufacturing centers in Europe and Asia.

Smiths Medical: Accounted for 390 million catheter units in 2024, particularly dominating the U.S. and Canadian hospital markets with safety-engineered and antimicrobial-coated IV catheters.

Investment Analysis and Opportunities

In 2024, global investment in peripheral IV catheter production, innovation, and distribution infrastructure exceeded $1.3 billion. Asia-Pacific received over $520 million in new manufacturing investments to meet rising demand. China commissioned six new catheter production plants in Shandong, Zhejiang, and Guangdong, each with annual capacity above 80 million units. India added two catheter sterilization facilities with government support, boosting local availability by 54%.

North America attracted more than $400 million in R&D and facility upgrades. Smiths Medical expanded its Minnesota production facility by 220,000 sq ft, increasing output by 120 million catheters annually. B. Braun invested $98 million in an automated safety-integrated catheter line in Pennsylvania, cutting assembly time by 22%. Venture capitalists injected over $85 million into startups developing antimicrobial coatings and wireless IV patency monitoring.

European countries collectively invested more than $260 million. Germany directed $48 million toward sustainable manufacturing and recyclable packaging innovations, while Italy issued a national tender for 140 million IV catheters annually. France added two regional sterilization hubs supporting catheter distribution across Southern and Eastern Europe.

The Middle East & Africa received $160 million in combined public-private investment. Saudi Arabia built a centralized procurement and repackaging unit to distribute over 40 million units to regional hospitals. South African manufacturers secured $22 million for low-cost catheter production and rural clinic training programs.

Future investment opportunities include AI-driven vein visualization devices compatible with IV insertion, now piloted in more than 180 hospitals worldwide. Disposable IV catheter kits bundled with securement, flushing, and patient tracking systems gained traction, especially in outpatient surgery networks. Emerging markets such as Vietnam, Kenya, and Egypt received $34 million in localization initiatives aimed at reducing import dependency.

New Product Development

Innovation surged in 2024, with over 65 new peripheral IV catheter models launched. Smiths Medical introduced a dual-port integrated PIVC enabling simultaneous medication and fluid administration, selling more than 22 million units in eight months across 310 hospitals. TERUMO released a pediatric-specific catheter with a flexible polyurethane tip, shipping over 12 million units to hospitals in Japan, South Korea, and Germany.

Braun’s antimicrobial range, featuring a silver-embedded hub and ethanol-resistant tubing, demonstrated a 39% reduction in bacterial growth in ICU trials across 19 facilities. AngioDynamics debuted an NFC-enabled smart catheter that tracks type, lot, and dwell time, with 78,000 units tested in 56 hospitals. Global Medikit launched a biodegradable thermoplastic catheter line adopted by 140 public hospitals in Africa and India.

Hospira’s hydrophilic-coated catheters achieved insertion times under 42 seconds in 17% of U.S. post-operative procedures, while RenovoRx’s closed-system catheter reduced leakage by 61% in oncology applications. Design enhancements such as reinforced wings, transparent hubs, and non-slip grips improved handling, and 38% of new PIVCs featured color-coded size identifiers and barcoded packaging.

Five Recent Developments

B. Braun launched an antimicrobial closed-system catheter line, deploying 27 million units across 37 countries by Q4 2024.
Smiths Medical expanded its U.S. facility, boosting capacity by 120 million units annually and introducing a new dual-port PIVC.
TERUMO CORPORATION rolled out pediatric-flex catheter designs, adopted by over 750 pediatric hospitals worldwide.
AngioDynamics unveiled an NFC-enabled smart PIVC system, tested in 78,000 cases across North America and Europe.
Global Medikit launched the first biodegradable PIVC in emerging markets, delivering 9.4 million units to public hospitals in India and Kenya.

Report Coverage of Peripheral Intravenous (IV) Catheter Market

The peripheral IV catheter market report provides extensive coverage across product type, application setting, regional demand, regulatory environment, technological advancement, and manufacturer competitiveness. With global consumption exceeding 2.3 billion units in 2024, the report evaluates market drivers through verified usage data across hospitals, clinics, and ambulatory settings.

Key sections include performance benchmarking between short PIVCs and integrated systems, usage trends by specialty departments, and material preferences such as polyurethane, silicone, and antimicrobial coatings. More than 160 catheter SKUs are analyzed for insertion success rate, dwell time, and complication incidence.

The report highlights over 110 regulatory pathways across major regions, tracking approval durations and compliance challenges. Distribution models—OEM production, private labeling, and third-party bundling—are assessed alongside automation, sterilization, and packaging trends.

Investment insights cover capital expenditures, manufacturing expansions, and emerging digital tracking technologies, with future scenarios modeled using data from 75 national health systems and 450 hospital procurement departments. Featuring over 2,000 figures, graphs, and data tables, the report equips manufacturers, hospital buyers, health ministries, and investors with strategic intelligence for engaging in this critical medical device sector.